Skip to main content

Table 1 Baseline characteristics of HFpEF patients and age- and sex-matched controls

From: Associations and prognostic significance of diffuse myocardial fibrosis by cardiovascular magnetic resonance in heart failure with preserved ejection fraction

  HFpEF (n = 118) Healthy Controls (n = 26) P
Age (years) 78 ± 8 76 ± 5 0.28
Body mass index (kg/m2) 29 ± 7 25 ± 4 0.011
Female (n, %) 74 (63) 16 (62) 0.91
Heart rate (bpm) 73 ± 14 67 ± 9 0.040
Systolic blood pressure (mmHg) 136 ± 21 144 ± 22 0.069
Diastolic blood pressure (mmHg) 75 ± 13 82 ± 12 0.014
NYHA functional class III-IV (n, %) 53 (45) 0 (0) < 0.001
Medical history
 Atrial fibrillation (n, %) 73 (62) 0 (0) < 0.001
 Ischemic cardiomyopathy (n, %) 39 (33) 0 (0) < 0.001
 Previous valvular surgery (n, %) 12 (10) 0 (0) 0.12
 Previous heart failure episode 84 (71) 0 (0) < 0.001
Cardiovascular risk factors
 Smoking (n, %) 47 (40) 6 (23) 0.10
 Hypertension (n, %) 109 (93) 16 (62) < 0.001
 Diabetes (n, %) 46 (39) 1 (4) < 0.001
 Family history of cardiovascular disease (n, %) 24 (21) 3 (12) 0.40
 Hypercholesterolemia (n, %) 78 (67) 23 (88) 0.027
Medication
 Diuretics other than MRA (n, %) 94 (80) 2 (8) < 0.001
 MRA (n, %) 23 (19) 0 (0) 0.01
 Beta-blockers (n, %) 76 (64) 3 (12) < 0.001
 ACE-I or ARB (n, %) 76 (64) 9 (35) 0.005
 Statins (n, %) 54 (46) 5 (19) 0.01
Laboratory characteristics
 eGFR (ml/min/1.73 m2) 59 ± 23 70 ± 18 0.018
 Hemoglobin (g/dl) 11.8 ± 1.9 14.0 ± 1.3 < 0.001
 NT-proBNP (pg/ml) 1747 [374; 34,306] £ 111 [29; 393] £ 0.001
  1. £ Median [min; max]
  2. ACE-I angiotensin converting enzyme inhibitor, ARB angiotensin receptor blocker, eGFR estimated glomerular filtration rate; MRA: